Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2021
Bio-Thera and Pharmapark expand their partnership for BAT2206
Bio-Thera announced licensing and supply agreements with Pharmapark for BAT2206, granting Pharmapark exclusive rights to distribute and market the biosimilar in Russia and other CIS countries.
2021
Bio-Thera and Hikma enter BAT2206 commercialization and license agreement
Bio-Thera Solutions entered into a commercialization and license agreement with Hikma Pharmaceuticals for BAT2206. Hikma received exclusive rights to commercialize the product in the US, while Bio-Thera retained responsibility for development, manufacturing, and supply.
2020
Bio-Thera and BeiGene sign China agreement for BAT1706
Bio-Thera and BeiGene announced that they had signed an agreement covering the licensing, distribution and supply of Bio-Thera’s investigational biosimilar BAT1706 in China, including Hong Kong, Macao and Taiwan. The agreement was subject to approval at Bio-Thera’s September 2020 shareholders’ meeting.
2020
Bio-Thera announces proposed Hong Kong listing
Bio-Thera announced that its board had approved a proposal to issue H shares and apply for a main-board listing on the Hong Kong Stock Exchange. The company said it would choose an appropriate time and issuance window within the period authorized by the shareholders’ meeting.
2020
Bio-Thera announces plan for Hong Kong listing
Bio-Thera announced that its board had approved a proposal to issue H shares and apply for a listing on the main board of the Hong Kong Stock Exchange. The company said the timing would be determined later, subject to shareholder authorization, market conditions, and regulatory approvals.
2019
Bio-Thera Therapeutics passed STAR Market IPO review
The Shanghai Stock Exchange's STAR Market Listing Committee review results stated that Bio-Thera Therapeutics' STAR Market IPO passed review.
2019
China approves Bio-Thera’s BAT1406
China’s National Medical Products Administration approved Bio-Thera’s adalimumab biosimilar BAT1406 for marketing in early November 2019, making it the company’s first approved marketed drug and the first approved domestic biosimilar to Humira.